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Abstract
Adipose tissue (AT) inflammation leads to increased free fatty acid (FFA) efflux and ectopic fat deposition, but
whether AT dysfunction drives selective fat accumulation in specific sites remains unknown. The aim of the present
study was to investigate the correlation between AT dysfunction, hepatic/pancreatic fat fraction (HFF, PFF) and the
associated metabolic phenotype in patients with Type 2 diabetes (T2D). Sixty-five consecutive T2D patients were
recruited at the Diabetes Centre of Sapienza University, Rome, Italy. The study population underwent clinical
examination and blood sampling for routine biochemistry and calculation of insulin secretion [homoeostasis model
assessment of insulin secretion (HOMA-β%)] and insulin-resistance [homoeostasis model assessment of insulin
resistance (HOMA-IR) and adipose tissue insulin resistance (ADIPO-IR)] indexes. Subcutaneous (SAT) and visceral
(VAT) AT area, HFF and PFF were determined by magnetic resonance. Some 55.4% of T2D patients had
non-alcoholic fatty liver disease (NAFLD); they were significantly younger and more insulin-resistant than non-NAFLD
subjects. ADIPO-IR was the main determinant of HFF independently of age, sex, HOMA-IR, VAT, SAT and predicted
severe NAFLD with the area under the receiver operating characteristic curve (AUROC) = 0.796 (95% confidence
interval: 0.65–0.94, P= 0.001). PFF was independently associated with increased total adiposity but did not
correlate with AT dysfunction, insulin resistance and secretion or NAFLD. The ADIPO-IR index was capable of
predicting NAFLD independently of all confounders, whereas it did not seem to be related to intrapancreatic fat
deposition; unlike HFF, higher PFF was not associated with relevant alterations in the metabolic profile. In
conclusion, the presence and severity of AT dysfunction may drive ectopic fat accumulation towards specific targets,
such as VAT and liver, therefore evaluation of AT dysfunction may contribute to the identification of different risk
profiles among T2D patients.
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INTRODUCTION
Adipose tissue (AT) is an endocrine organ able to influence both
systemic inflammation and metabolic homoeostasis; in condi-
tions of caloric excess it produces and releases into the blood-
stream several pro-inflammatory cytokines, the ‘adipokines’,
leading to low-grade chronic inflammation and the metabolic
Abbreviations: ADIPO-IR, adipose tissue insulin resistance; ALT, alanine aminotransferase; AST, aspartate aminotransferase; AT, adipose tissue; AUROC, area under the receiver
operating characteristic curve; BMI, body mass index; C.I., confidence interval; CRP, C-reactive protein; DBP, diastolic blood pressure; FBG, fasting blood glucose; FBI, fasting blood
insulin; FFA, free fatty acid; FLI, fatty liver index; GRE, gradient echo; HbA1c, glycosylated haemoglobin; HDL-C, high-density lipoprotein cholesterol; HFF, hepatic fat fraction; HOMA-IR,
homoeostasis model assessment of insulin resistance; HOMA-β%, homoeostasis model assessment of insulin secretion; IP, in-phase; LDL-C, low-density lipoprotein cholesterol;
NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis; OP, opposed-phase; PFF, pancreatic fat fraction; ROI, region of interest; SAT, subcutaneous adipose tissue;
SBP, systolic blood pressure; T2D, Type 2 diabetes; VAT, visceral adipose tissue; γ -GT, γ -glutamyl transpeptidase.
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complications of obesity [1]. Thus, the chronic inflammatory
state may provide an explanation of the well-known relationship
between obesity and insulin resistance [2]. Furthermore, anatom-
ical and functional AT rearrangements that occur in obesity, i.e.
adipocyte hypertrophy and hyperplasia, lead to hypoxia, adipo-
cyte death and attraction of active macrophages surrounding the
adipocytes in crown-like structure [3]. In such a scenario, the AT
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insulin resistance and its capability of storing triacylglycerols is
drastically reduced, alongwith an increased lipolytic activity. This
promotes a hyper-afflux of free fatty acids (FFAs) into the blood-
stream and aberrant fat deposition in non-ATs [1]. An excessive
intrahepatic fat accumulation is the hallmark of non-alcoholic
fatty liver disease (NAFLD), a condition potentially evolving
into non-alcoholic steatohepatitis (NASH), cirrhosis, liver fail-
ure and hepatocarcinoma [4,5]. NAFLD represents nowadays the
most common liver disorder in the Western world [6] and is
an emerging independent risk factor for cardiovascular disease
[7]. A strong association between NAFLD and Type 2 diabetes
(T2D) has been demonstrated: more than 90% of obese patients
with T2D have NAFLD, and the link between these two univer-
sally widespread conditions is represented by insulin resistance
[8]. Furthermore, lipid deposition in the hepatocytes leads to
a critical reduction in hepatic insulin sensitivity, resulting in a
deregulation of glucose/insulin homoeostasis, systemic insulin
resistance and increased fasting glucose levels [9–12]. More re-
cently, the intrapancreatic fat accumulation has been suggested
as a pathological condition itself, with an increased prevalence in
obese subjects and in individuals with the metabolic syndrome
and diabetes [13,14]. Some studies investigated the impact of
pancreatic fat content on β-cell function in both healthy people
and subjects with impaired glucose regulation, but evidence is
contrasting [15–20]. In children, fatty pancreas seems to repres-
ent a hallmark of metabolic impairment [21]; however, its role
in insulin secretion and metabolic control in T2D patients is still
unknown and, very recently, even the existence itself of an in-
trapancreatic – and not just peripancreatic – fat accumulation,
has been questioned [20,22,23]. Furthermore, to the best of our
knowledge, no study has investigated whether fat deposition into
the pancreas is mediated by AT dysfunction, as in NAFLD, and
whether fatty pancreas could represent an additional marker of
AT inflammation andmetabolic impairment in patients with T2D.
Therefore, the aim of the present study was to study the as-
sociation between the presence and severity of AT dysfunction,
quantified by the histologically validated adipose tissue insulin
resistance (ADIPO-IR) index, and fat accumulation both in liver
and pancreas in an adult population of T2D patients. We also
tested the hypothesis of an influence of AT dysfunction in orient-
ing fat localization towards specific targets, such as subcutaneous
(SAT) or visceral (VAT) AT compartments. Finally, we sought a
different role of hepatic fat fraction (HFF) and pancreatic fat frac-
tion (PFF) in identifying different risk profiles among diabetes
patients.
MATERIALS AND METHODS
Study population
For this purpose, we analysed the cross-sectional data
derived from the population of the Eudract 2011-
003010-17 study (European Union Clinical Trials Register,
http://www.clinicaltrialsregister.eu), a randomized controlled
trial aiming to evaluate the efficacy and safety of oral vitamin
D supplementation in T2D patients with NAFLD [24]. The study
protocol was reviewed and approved by the Ethics Committee of
this hospital and the study was conducted in conformance with
the Helsinki Declaration. Written informed consent was obtained
from all patients before the study.
Sixty-seven patients affected by T2D and with clinical suspi-
cion of NAFLD [increased serum transaminases levels, low as-
partate aminotransferase (AST)/alanine aminotransferase (ALT)
ratio and/or ultrasound-detected fatty liver in the absence of
known hepatic chronic disease] were selected among those re-
ferring to our Diabetes Outpatients Clinics, Sapienza University
of Rome, Rome, Italy, for routine diabetes care. Two subjects
withdrew their consent to study participation before undergoing
abdominal magnetic resonance (MRI).
To be eligible for the study, patients had to fulfil the following
criteria: male or female subjects with a diagnosis of T2D, 25–
70 years of age, no history of current or past excessive alcohol
drinking, as defined by an average daily consumption of alcohol
<30 g/day in men and <20 g/day in women, negative tests for
the presence of hepatitis B surface antigen and antibody against
hepatitis C virus, absence of history and findings consistent with
cirrhosis and other chronic liver diseases.
All subjects underwent a complete work-up including a clin-
ical examination, anthropometric measurements and laboratory
tests. Weight and height were measured with patients wearing
light clothing and no shoes. The body mass index (BMI) was
calculated as weight in kg divided by the square of the height
in m (kg/m2). Waist circumference (cm) was measured midway
between the 12th rib and the iliac crest. Systemic blood pressure
(systolic, SBP; diastolic, DBP; mmHg) was measured after 5 min
of rest using an electronic auscultatory blood pressure recorder
with an appropriately sized cuff based on the measurement of
arm circumference with the patient sitting in the upright position.
Threemeasurementswere recorded, and the average of the second
and third measurement was recorded and used in the analyses.
Abdominal MRI was performed to assess HFF and PFF (%)
and to measure SAT and VAT (cm2).
Laboratory determinations
The study population underwent fasting blood sampling to as-
sess blood glucose (FBG, mg/dl), glycosylated haemoglobin
(HbA1c, %, mmol/l), total cholesterol (mg/dl), high-density lipo-
protein cholesterol (HDL-C, mg/dl), triacylglycerols (mg/dl),
AST (IU/l), ALT (IU/l), γ -glutamyl transpeptidase (γ -GT, IU/l)
and C-reactive protein (CRP, mg/dl) by standard laboratorymeth-
ods. Serum insulin [fasting blood insulin (FBI), μ-units/l] was
measured by radio immuno assay (Pantec; intra- and inter-assay
coefficients of variation <5%), FFAs, (mg/dl) by colorimetric
methods (Bios) and circulating adiponectin levels (μg/ml) were
assessed by enzyme-linked immunosorbent assay (ELISA) (Tema
Ricerca; intra- and inter-assay coefficients of variation 5%).
The low-density lipoprotein cholesterol (LDL-C, mg/dl)
value was calculated using the Friedwald formula. The homoeo-
stasis model assessment of insulin resistance (HOMA-IR) and
insulin secretion (HOMA-β%) were calculated as previously
described [25], the AT insulin resistance was quantified by the
ADIPO-IR index [FFAs (μmol/l) × FBI (μU/l)] [26–28]. The
fatty liver index (FLI), a clinical correlate of NAFLD, was also
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calculated in the whole study population [29]. Diabetes mellitus
was diagnosed according to American Diabetes Association
(ADA) 2009 criteria [30].
MRI evaluations
All MRI evaluations were performed by the same operator, un-
aware of the study aims and blinded to laboratory values, using
a 1.5-T magnet (Magnetom Avanto, Siemens Medical Systems)
equipped with a phased-array surface coil and a spine array coil.
Image acquisition was performed in the axial plane during an
end-expiratory breath-hold using a sensitivity encoding (SENSE)
technique in order to reduce the overall acquisition time to ap-
proximately 15 s. HFF and PFF were obtained by using a 2D
spoiled gradient echo (GRE) acquired on the axial plane. To
minimize T1 effects, a low flip angle (10◦) was used at a repe-
tition time of 150 ms. To estimate fat-water signal interference
and T2* effects, three echoes were obtained at serial opposed-
phase (OP) and in-phase (IP) echo times (2.3, 4.7 and 6.9 ms);
other parameters applied were: section thickness, 5 mm; matrix
size, 256× 182; field of view, 35 cm × 40 cm. HFF and PFF
were calculated from the mean of the two IP sequences (IP cor-
rect) with the OP sequence subtracted and then divided by the
‘2× IP correct’ sequence. For HFF, eight different regions of in-
terest (ROIs) measuring 2 cm2 were drawn, one for each hepatic
segment within the liver, avoiding areas with vessels, motion arte-
facts and partial volume effects; ROIs were placed at anatomic-
allymatched locations on paired images by using a co-registration
tool available on the picture archiving and communication system
workstation. Finally, mean+−S.D. HFF was calculated for each
patient and NAFLD was diagnosed in the presence of mean HFF
 5.5% [31]. For PFF, three ROIs of 0.5 cm2 were placed respect-
ively in the pancreas’s head, body and tail, in areas with homogen-
eous fat distribution and far from the pancreas borders, in order
to avoid bias related to the presence of peripancreatic visceral fat.
For VAT and SAT quantification, a 3D GRE T1-weighted
volume-interpolated breath-hold examination (VIBE) sequence
on axial plane modified by Dixon was acquired [repetition time
(TR), 4.7 ms; echo time (TE), 2.3 ms; flip-angle, 10 ◦C; mat-
rix, 256 mm×192 mm; section thickness, 5 mm, reconstructed
2.5 mm; intersection gap, 0]. The fat-only datasets were trans-
ferred to a personal computer for analysis using commercially
available software (Slice-O-Matic; Tomovision); the detailed pro-
cedures are described elsewhere [31–33]. Briefly, data were cal-
culated fromAT area at L1–L2, L2–L3, L3–L4 and L4–L5 levels;
a free-form ROI and manual threshold were used to select fat tis-
sue within VAT and SAT slides. Mean+−S.D. VAT and SAT areas
were then calculated in each patient for statistical purposes.
Statistics
SPSS version 23 statistical package was used to perform all the
analyses. Values are reported as means+−S.D. for continuous
variables and as a percentage for categorical variables. Compar-
isons between two groups were performed by the non-parametric
Kruskal–Wallis test for continuous variables and Pearson’s χ2
test for categorical variables. Bivariate correlation analyses were
calculated by Spearman’s rank correlation or by age–sex-adjusted
partial correlation test; the multivariate regression model in-
cluded sex and age and all the variables were statistically sig-
nificant at the bivariate correlation analysis. A two-tailed P value
< 0.05 was considered statistically significant, with a confidence
interval (C.I.) of 95%.
RESULTS
AT insulin resistance and NAFLD
The prevalence of NAFLD in our study population was 55.4%
(n= 36/65); T2D patients with NAFLD were significantly
younger (56.2+− 9.7 compared with 61.7+− 8.8 years, P= 0.01)
despite comparable diabetes duration, and more insulin resist-
ant (HOMA-IR: 14+− 5.1 compared with 10.2+− 5.3, P= 0.004,
ADIPO-IR: 7.3+− 3.9 compared with 5+− 4.6, P= 0.008) than
subjects without NAFLD.
Blood lipids and glycaemic control, as expressed by FBG,
HbA1c and diabetes treatment (type and number of oral antidia-
betic agents, insulin therapy) were comparable between the two
subgroups. T2D patients with NAFLD had double serum CRP
levels than non-NAFLD subjects. Clinical and biochemical para-
meters of T2D patients according to the presence of NAFLD
are shown in Table 1. The differences found in insulin-derived
indexes between T2D individuals with and without NAFLD per-
sisted after the exclusion of insulin-treated patients (n= 11) from
thewhole study population (results not shown). T2Dpatients with
NAFLD had comparable mean PFF, VAT and SAT with those
without NAFLD (PFF: 5.1+− 5% compared with 5.4+− 5.3%,
P= 0.8; VAT: 195.2+− 74.6 cm2 compared with 184.5+− 69.3
cm2, P= 0.56; SAT: 255.1+− 130.1 cm2 compared with 219.6+−
108.8 cm2, P= 0.23).
The bivariate correlation analysis showed that an increased
HFF, considered as a continuous variable, was associated with
higher serum transaminases and FBI, low AST/ALT ratio and
greater AT dysfunction and insulin resistance (Table 2); notably,
multivariate logistic regression analysis demonstrated that greater
ADIPO-IR was a determinant of increased HFF independent of
sex, age and all the metabolic confounders (standardized β: 0.41,
P= 0.012). The area under the receiver operating characteristic
curve (AUROC) of ADIPO-IR for predicting the presence of
severe NAFLD, considered as belonging to the highest quartile
of HFF, was 0.796 (C.I. 95%: 0.65–0.94, P< 0.001); an ADIPO-
IR greater than 6.9 mmol/l·μ-units/ml was able to predict severe
NAFLD with a sensitivity of 84.6% and a specificity of 79.1%
(Figure 1).
In the whole study population, higher ADIPO-IR correl-
ated with the presence of obesity, atherogenic dyslipidaemia,
increased serum transaminases and CRP levels, FLI, HFF, VAT
and whole-body insulin resistance, but was not associated with
sex, age and T2D duration (Table 3). Fitting into the highest
ADIPO-IR quartile (worse AT insulin resistance) significantly
predicted the presence of NAFLD in T2D patients, with odds
ratio (OR): 3.3 (C.I. 95%: 1.1–9.8, P= 0.032, χ2 test).
AT insulin resistance and PFF
Our study population had a mean+−S.D. PFF of 5.2+− 5%,
significantly higher than that reported in a historical control
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Table 1 Clinical and biochemical characteristics of T2D patients with and without NAFLD (cut-off HF content: 5.5 % by MRI).
n.s., not significant. Mann–Whitney test, except *χ2 test, †ANOVA test.
NAFLD (n= 36) Non-NAFLD (n= 29) P-value
Age (years) 56.2+−9.7 61.7+−8.8 0.010
Sex (males/females) 26/10 21/8 n.s.*
BMI (kg/m2) 30.4 +− 4.4 29.4 +− 4.2 n.s.
Waist circumference (cm) 106.2 +− 14.2 100.4 +− 10.2 n.s.
T2D duration (years) 6 +− 5 8.3 +− 8 n.s.
SBP (mmHg) 127.5 +− 16.3 133.9 +− 16.6 n.s.
DBP (mmHg) 81 +− 9.6 81.8 +− 10.4 n.s.
Total cholesterol (mg/dl) 176.2 +− 36.9 176.4 +− 38.1 n.s.
HDL-C (mg/dl) 48.4 +− 15.1 49.9 +− 12.9 n.s.
LDL-C (mg/dl) 100.7 +− 35.1 98.9 +− 31.4 n.s.
Triacylglycerols (mg/dl) 135 +− 65.8 137.3 +− 59 n.s.
FBG (mg/dl) 130.4 +− 32.3 134.8 +− 46 n.s.
HbA1c (%/mmol/mol) 6.7 +− 1/50 +− 10 6.5 +− 0.9/48 +− 8 n.s.
AST (IU/l) 26.9 +− 13.3 20.8 +− 11.5 0.012
ALT (IU/l) 39.6 +− 25.2 24.3 +− 12.1 0.001
γ -GT (IU/l) 51.2 +− 61.7 32.3 +− 33.2 n.s.
AST/ALT 0.74 +− 0.2 0.92 +− 0.3 0.005
FFAs (μmol/l) 549.2 +− 281 484.8 +− 215.5 n.s.
FBI (μ-units/l) 14 +− 5.1 10.2 +− 5.3 0.004
FLI 70.2 +− 23.3 59.3 +− 26.1 n.s.
HOMA-IR 4.4 +− 1.6 3.2 +− 1.9 0.025
HOMA-β% 103.3 +− 72.2 70.8 +− 48.8 n.s.
Quantitative insulin sensitivity check index (QUICKI) 0.31 +− 0.02 0.33 +− 0.03 0.025
ADIPO-IR 7.3 +− 3.9 5 +− 4.6 0.008
CRP 4.2 +− 5 2.1 +− 2.7 0.05
Adiponectin (μg/ml) 6.5 +− 3 6.1 +− 3.8 n.s.
Insulin treatment (n patients/%) 4/9 7/28 n.s.*
Number of oral anti-diabetic agents (% patients)
0 12 15 n.s.†
1 47 43
2 32 27
3 9 15
Statin treatment (n patients/%) 18/52 18/64 n.s.*
Anti-hypertensive treatment (n patients/%) 29/80 21/72 n.s.*
cohort of sex- and age-matched healthy controls recruited in our
centre (n= 30, males/females: 21/9, age: 55.1+− 7.9 years; PFF:
3+− 2%, P< 0.05). Patients with T2D within the highest PFF
quartilewere significantly older and had increasedBMI,waist cir-
cumference, SBP and serumCRP levels in comparisonwith those
in the lowest PFF quartile (Table 4). Moreover, although patients
with the highest PFF showed a trend to worse glycaemic control
despite a higher rate of insulin-treated subjects, the positive
association between PFF and HbA1c disappeared after removing
the effect of sex and age (partial bivariate correlation: r= 0.23,
P= 0.065).
Whereas PFF was significantly associated with age (r= 0.30,
P= 0.01), T2D duration (r= 0.37, P= 0.002), BMI (r= 0.31,
P= 0.012), waist circumference (r= 0.30, P= 0.016), and both
VAT and SAT area (r= 0.29, P= 0.02; r= 0.37, P= 0.002), no
correlationwas found between increased PFF andATdysfunction
(ADIPO-IR: r= 0.09, P= 0.50), HOMA-IR (r= 0.02, P= 0.85)
and HOMA-β% (r= 0.01, P= 0.92) at the bivariate correlation
analyses.
Interestingly, a higher PFF was not associated with the dia-
gnosis ofNAFLD (r=−0.09,P= 0.43), orwithHFF (r=−0.11,
P= 0.38) and serum transaminases (AST: r=−0.09, P= 0.48;
ALT: r=−0.21, P= 0.09; γ -GT: r=−0.16, P= 0.21); the par-
tial correlation analysis confirmed the lack of an association
between PFF andHFF even after removing the sex/age effect (r=
−0.075, P= 0.56).
Finally, an increased adiposity, as expressed by BMI, and not
the AT insulin resistance, strongly predicted higher PFF inde-
pendently of all clinical and metabolic confounders (R2 = 0.32,
P= 0.012; Table 5).
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Figure 1 ADIPO-IR AUROC for severe NAFLD
AT insulin resistance, VAT and SAT area
Mean VAT area was significantly higher in T2D males than in
females (202.8+− 74.2 cm2 compared with 158.4+− 55.7 cm2,
P= 0.013) as opposed to mean SAT area which was greater in
female than male participants (314.5+− 103.2 cm2 compared with
210.4+− 116.3 cm2, P= 0.001).
Age and sex-adjusted partial bivariate analyses showed the
existence of a significant association between increased VAT
area and higher ADIPO-IR (r= 0.28, P= 0.035), SBP (r= 0.32,
P= 0.029), FBI and HOMA-IR (r= 0.37, P= 0.024; r= 0.40,
P= 0.005), FLI (r= 0.6, P< 0.001), CRP (r= 0.48, P< 0.001)
and low HDL-C (r=−0.29, P= 0.04); higher VAT area also
correlated with higher PFF (r= 0.45, P< 0.001) but not with
higher HFF (r= 0.18, P= 0.21), serum adiponectin (r=−0.16,
P= 0.21) and FFA concentration (r= 0.05, P= 0.71).
As formean SAT area, no associationwas foundwithADIPO-
IR (r= 0.06, P= 0.7) and all other clinical and biochemical
markers of metabolic disease, although increased SAT area sig-
nificantly correlated with higher CRP levels (r= 0.36, P= 0.01)
and PFF (r= 0.45, P< 0.001).
AT insulin resistance and systemic inflammation
In T2D patients, increased serum CRP levels were asso-
ciated with greater ADIPO-IR (r= 0.35, P= 0.008), BMI
(r= 0.44, P< 0.001), waist circumference (r= 0.38, P= 0.003),
SAT (r= 0.50, P< 0.001), DBP (r= 0.26, P= 0.04) and FLI
(r= 0.46, P< 0.001).
In order to identify clinical and metabolic correlates of in-
creased CRP levels in T2D non-obese patients, we excluded from
the analysis all subjects with a BMI > 29.9 kg/m2 and found
that in the non-obese subgroup (n= 31 patients, 48%) higher
CRP concentrations characterized T2D patients with NAFLD +
worse AT dysfunction (as expressed by ADIPO-IR above the me-
dian value), compared with those with NAFLD but low ADIPO-
IR, and were associated with worse liver inflammation (AST
P< 0.001, ALT P= 0.01, γ -GT P= 0.02).
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Table 2 HFF % – bivariate correlation analyses (Spearman’s
coefficient, continuous variable)
Correlation coefficient P-value
HOMA-IR 0.32 0.015
ADIPO-IR 0.41 0.002
Age −0.29 0.019
AST 0.49 <0.001
ALT 0.57 <0.001
γ -GT 0.38 0.002
FBI 0.36 0.006
Quantitative insulin sensitivity
check index (QUICKI) −0.32 0.015
AST/ALT −0.41 <0.001
DISCUSSION
In the present study we demonstrated that the occurrence of
NAFLD in patients with T2D is linked to the presence of AT
dysfunction whereas fat accumulation into the pancreas does
not appear to be associated with AT dysfunction and insulin-
resistance.
Our results, indeed, point towards the existence of a marked
heterogeneity in intraparenchymal fat accumulation among pa-
tients with T2D, with a pattern of distribution which appears to
be related more to AT dysfunction than to adiposity itself.
As far as we are aware, this is the first study investigating
the association between AT dysfunction and intrapancreatic fat
accumulation, even in relation to the presence of NAFLD.
Over half of our population of T2D patients hadMRI-detected
fatty liver; NAFLD was more prevalent in younger subjects with
worse insulin resistance and AT dysfunction, regardless of total
adiposity, diabetes duration, therapy and metabolic control. A
number of studies found a correlation between HFF and visceral
adiposity in the general population and between liver inflamma-
tion andfibrosis andVATarea among subjectswith biopsy-proven
NASH [31,34–36]. Our study demonstrated that in T2D patients,
a population with increased VAT area and aberrant VAT/SAT
ratio by definition, the main determinant of high HFF is AT dys-
function, and then AT resistance to insulin action, independent
of BMI and total adiposity. Moreover, we were able to identify a
cut-off value of ADIPO-IR predictive of the presence of severe
NAFLD in T2D patients, therefore allowing us to stratify the risk
of NASH and, subsequently, liver-related complications [4,5] and
cardiovascular disease [8] in this population.
The ADIPO-IR threshold we detected is in line with the mean
values reported in obese patients with NAFLD, which is 4-fold
higher than that of healthy obese subjects or lean individuals
without NAFLD and T2D [28]. In our population, we identified
a remarkable heterogeneity of AT dysfunction severity, mostly
related to greater insulin resistance, higher HFF, serum liver
enzymes, CRP, presence of atherogenic dyslipidaemia and in-
creased fat storage into the VAT – but not SAT – compartment. In
agreement with our results, du Plessis et al. [37] recently demon-
strated the association between NAFLD/NASH and the expres-
Table 3 ADIPO-IR – bivariate correlation analyses
(Spearman’s coefficient, continuous variable)
n.s., not significant.
Correlation coefficient P-value
Age −0.11 n.s.
Sex (M/F) 0.20 n.s.
T2D duration −0.10 n.s.
BMI −0.31 0.019
PAD 0.45 <0.001
HDL-C −0.29 0.03
Triacylglycerols 0.36 0.006
AST 0.27 0.04
ALT 0.32 0.01
γ -GT 0.28 0.04
CRP 0.35 0.008
HOMA-IR 0.58 <0.001
HOMA-β% 0.30 0.025
Quantitative insulin sensitivity
check index (QUICKI) −0.58 <0.001
FLI 0.40 0.003
HFF 0.41 0.002
NAFLD (yes/no) (NMR) 0.36 0.007
Obesity (yes/no) 0.31 0.02
VAT 0.28 0.035
SAT 0.22 0.10
sion of pro-inflammatory cytokines in AT biopsies of morbidly
obese subjects. As AT remodelling leads to increased FFA ef-
flux into the bloodstream and fat accumulation into the liver, we
investigated whether AT dysfunction could determine aberrant
fat storage in pancreatic parenchyma as well, and, thus, whether
pancreatic steatosis could represent an additional marker of AT
inflammation and metabolic impairment in patients with T2D.
Indeed, the main determinant of increased intrapancreatic fat ac-
cumulation was total adiposity, in terms of higher BMI, SAT
and VAT areas, whereas no correlation was found between PFF
and AT dysfunction, systemic insulin resistance and insulin se-
cretion. Ultrasound-detected fatty pancreas has been associated
with metabolic syndrome and its components in cohorts of con-
secutive subjects and in some case–control studies [13,14,38].
Contrariwise, the pancreatic parenchymal fat distribution within
a population of T2D patients was assessed byMRI and quantified
by specific software, thus excluding peripancreatic fat from the
mean PFF. In agreement with Wong et al. [19], reporting an asso-
ciation between MRI-detected PFF and central adiposity, but not
insulin secretion, in a large cohort of healthy Chinese volunteers,
we did not find a correlation between PFF and either insulin
secretion or glycaemic control. So far, evidence on pancreatic
fat and its correlates in T2D patients is limited; although most
studies demonstrated an association between increased pancre-
atic fat content, age and total adiposity, data on PFF and insulin
secretion, in the presence of impaired glucose regulation or dia-
betes, are contrasting and far from being conclusive [15–18,20–
23,39]. Interestingly, we did not find any association between the
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Table 4 Clinical and biochemical characteristics of T2D patients according to PFF (I compared with IV quartile)
n.s., not significant. Mann–Whitney test, except *χ2 test, †ANOVA test.
Low PFF High PFF P-value
Pancreatic fat content (%) 0 +− 2 12.9 +− 5 <0.001
Age (years) 53.9 +− 11.7 63.4 +− 8.8 0.015
Sex (males/females) 15/1 10/6 0.03*
BMI (kg/m2) 27.7 +− 2.6 32.4 +− 5.4 0.005
Waist circumference (cm) 97.8 +− 5.4 109.6 +− 15.1 0.007
T2D duration (years) 4.5 +− 5 8.2 +− 7.9 n.s.
SBP (mmHg) 121.6 +− 11.8 139.2 +− 22 0.008
DBP (mmHg) 80 +− 7.3 83.9 +− 12.8 n.s.
Total cholesterol (mg/dl) 175.13 +− 44.3 179.1 +− 44.7 n.s.
HDL-C (mg/dl) 45.4 +− 10 52.3 +− 16.2 n.s.
LDL-C (mg/dl) 100 +− 37.3 99.1 +− 40.7 n.s.
Triacylglycerols (mg/dl) 148.2 +− 90.1 137.4 +− 56 n.s.
FBG (mg/dl) 124.2 +− 27.9 132.1 +− 41.2 n.s.
HbA1c (%/mmol/mol) 6.17 +− 0.7/44 +− 7 6.7 +− 0.9/50 +− 8 0.05
AST (IU/l) 22.6 +− 7.2 20.01 +− 5.7 n.s.
ALT (IU/l) 34.9 +− 18 24.8 +− 12.4 n.s.
γ -GT (IU/l) 34.3 +− 22.9 37.1 +− 57.8 n.s.
AST/ALT 0.7 +− 0.2 0.9 +− 0.3 0.03
FFAs (μmol/l) 484.9 +− 355.7 481.6 +− 181.4 n.s.
FBI (μ-unit/l) 12.9 +− 3.9 12.2 +− 4.3 n.s.
FLI 57.2 +− 19.3 71.7 +− 23.2 n.s.
HOMA-IR 3.8 +− 1.2 4 +− 1.8 n.s.
HOMA-β% 97 +− 71.4 82.2 +− 44.3 n.s.
Quantitative insulin sensitivity check index (QUICKI) 0.32 +− 0.02 0.32 +− 0.04 n.s.
ADIPO-IR 5.8 +− 4.6 5.8 +− 2.8 n.s.
CRP 1.2 +− 2 4.2 +− 4.5 0.03
Adiponectin (μg/ml) 6.3 +− 3.4 5.6 +− 3 n.s.
Insulin treatment (n patients/%) 0/0 3/31 0.02*
Number of oral anti-diabetic agents (% patients)
0 26.7 6.2 n.s.†
1 46.7 50
2 20 31.2
3 6.6 12.6
Statin treatment (n patients/%) 6/40 9/56 n.s.*
Anti-hypertensive treatment (n patients/%) 11/69 12/75 n.s.*
Table 5 Multivariate linear regression analysis
Dependent variable: PFF (%).
B S.D. β t P-value
(Constant) −0.185 0.084 −2.197 0.033
Age 0.001 0.001 0.116 0.879 0.384
Sex 0.025 0.017 0.193 1.458 0.152
BMI 0.005 0.002 0.379 2.622 0.012
ADIPO-IR 0.000 0.002 −0.020 −0.153 0.879
HbA1c 0.002 0.009 0.031 0.206 0.838
Insulin therapy 0.021 0.022 0.145 0.972 0.336
CRP 0.001 0.002 0.048 0.360 0.720
AST/ALT 0.029 0.027 0.138 1.067 0.291
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diagnosis of NAFLD and high PFF in T2D, differently from what
reported in healthy subjects [19,40] and in obese non diabetic in-
dividuals [41,42]. Therefore, in our study, specific parenchymal
fat distribution identified different phenotypes of T2D patients:
subjects with NAFLD were younger and had worse metabolic
profile than non-NAFLD subjects, whereas higher PFF identified
older patients with AT dysfunction and insulin secretion compar-
able with those found in T2D subjects with lower PFF.
Since adipocytes from VAT are more prone to lipolysis than
subcutaneous adipocytes [43,44], FFAs may flood directly from
VAT into the portal vein, exposing the liver to higher FFA levels
than those predictable from systemic FFA levels [45–47]. In an
elegant experiment of lipid physiology, Jensen et al. [47] tested a
model to predict the fraction of hepatic FFA delivery that arises
from VAT lipolysis. For this purpose, splanchnic palmitate kinet-
ics were measured in blood samples collected from the arterial,
portal venous and hepatic venous circulation of chronically cath-
eterized dogs under several experimental conditions. The overall
results showed that liver took up a large proportion of FFAs en-
tering the splanchnic bed through the portal vein, with only a
small fraction of FFAs being taken up by non-hepatic splanchnic
blood [47]. Furthermore, human studies showed that, in con-
ditions of hyperinsulinaemia, the circulating amount of FFAs
derived from VAT increases drastically, thus exposing the liver
to significantly greater FFA concentrations than the periphery.
This portal–systemic difference may be even higher in condi-
tion of visceral obesity [48]. Indeed, we may speculate that AT
dysfunction results in greater FFA flux into the portal system,
leading to hepatic, but not pancreatic, aberrant fat accumulation.
These data, along with our findings of comparable BMI, waist
circumference, VAT and SAT areas between NAFLD and non-
NAFLD diabetic patients, reinforce the assumption for a key role
of AT dysfunction in determining NAFLD in this population.
Conversely, evidence showed that greater waist circumference
and increased abdominal fat depend on both SAT and VAT ex-
pansion in the presence of inflamed and dysfunctional AT [49],
arising doubts on the exclusive role of VAT mass in causing
ectopic fat deposition and its complications [50,51]. Another
explanation of our findings comes from the striking evidence
that NAFLD itself is a determinant of insulin resistance [9–12]
and impaired insulin secretion [52], and represents an additional
risk factor for metabolic complications [53]. Our findings cor-
roborate in a clinical setting the bulk of the experimental data
on a direct role of fatty liver in driving and exacerbating the
progression of dysmetabolic conditions. In the presence of AT
dysfunction, once NAFLD is established, metabolic pathways
triggered by the intrahepatic fat accumulation may directly in-
duce detrimental outcomes in T2D patients, whereas other pro-
cesses, such as intrapancreatic fat accumulation, probably rep-
resent a consequence of an overall increased adiposity in this
population.
Despite the cross-sectional design of the present study, not
allowing us to establish a certain causal relationship, we may
speculate that intrapancreatic fat does not represent, itself, a risk
factor and/or amarker of furthermetabolic impairment in patients
with established diabetes, and, unlike NAFLD, is not directly
related to AT inflammation.
In conclusion, our findings suggest that the presence and
severity of AT dysfunction may determine ectopic fat distribution
towards specific targets, such as VAT and liver, thus identifying
different risk profiles in T2D patients and potentially represent-
ing a starting point for future research aimed at identifying novel
therapeutic approaches.
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